Domestic TB Funding Rises 14% as Global Treatment Gaps Persist
The WHO says governments are replacing some lost donor financing, but tuberculosis remains a major cause of preventable death.
Countries increased domestic spending on tuberculosis programs by 14% to $5.6 billion in 2025, partially offsetting a decline in international assistance, according to the World Health Organization’s newest assessment of the global disease burden.
The WHO Global Tuberculosis Report 2026 estimates that 10.6 million people developed tuberculosis in 2025 and about 1.13 million died. Disease incidence and mortality have declined, but progress remains slower than the milestones governments agreed under the End TB Strategy.
The report draws on submissions from 187 countries and areas representing more than 99% of the world’s population and estimated tuberculosis cases. It offers a broad picture of progress, while acknowledging that estimates can change as surveillance and statistical methods improve.
National financing takes a larger role
The WHO said domestic program funding increased partly because international financing fell by a similar amount. That shift matters because disease-control services require continuous staffing, medicine procurement, testing and follow-up rather than occasional campaigns.
A health ministry can expand its budget while still facing financing shortages if diagnostic demand rises or the cost of treatments increases. Funding levels must also be assessed against local purchasing power and the number of people who can actually obtain care.
For countries dependent on grants, maintaining gains may require predictable domestic financing and support to strengthen routine healthcare systems. Abrupt replacement of donor contributions can be difficult where public debt and competing spending demands are already high.
Better outcomes, unfinished work
The WHO estimates that tuberculosis deaths have fallen by about 35% since 2015. It also credits treatment with saving around 86 million lives since 2000. These estimates indicate substantial value from established services, not evidence that transmission has been brought under control.
Tuberculosis is curable for many patients, but diagnosis can be delayed because symptoms overlap with other illnesses or laboratory access is limited. People who begin treatment need reliable medication supplies and follow-up over months.
Drug resistance adds complexity and cost. New genetic testing tools can help clinicians choose suitable medicines, but those benefits depend on access to qualified laboratories and therapies.
Measuring the right progress
The global report emphasizes continued gaps in detection, prevention and treatment. Countries may report more diagnosed patients after expanding testing without an equivalent rise in infections. Conversely, weak reporting can conceal patients who never reach a clinic.
Comparable, updated national data are therefore essential. The WHO cautions against directly comparing burden estimates from older report editions when methods or time series have been revised.
Policy success should be judged by sustained declines in illness and death, faster access to appropriate treatment and reduced financial hardship for households.
A funding choice
The increase in national spending demonstrates political commitment, but disease programs remain vulnerable if countries cannot sustain the workforce, laboratories and medicines that produced earlier gains.
The WHO’s 2026 report is a reminder that tuberculosis control requires a long-term public-service system. Greater domestic funding is valuable precisely because the task remains unfinished.
Another measure of sustainability is whether people can complete treatment without losing income or access to food and housing. Health agencies increasingly examine the costs borne by patients, not only the medicines purchased by governments. Reducing those burdens can help prevent interrupted treatment and strengthen community confidence in tuberculosis services.